Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Impact of Inflammation and Treatment on Self-reported Quality of Life in Patients with Non-acute Vogt-Koyanagi-Harada Disease (VKHD)

Full text
Author(s):
Silveira Souto, Fernanda Maria [1] ; Brito Goncalves Missaka, Ruy Felippe [1] ; Magalhaes, Breno Marchiori [1] ; Couto Caetano, Victor Marcos [1] ; Takiuti, Julia Thiemi [1] ; Lavezzo, Marcelo Mendes [1] ; Sakata, Viviane Mayumi [1, 2] ; Oyamada, Maria Kiyoko [1] ; Hirata, Carlos Eduardo [1] ; Yamamoto, Joyce Hisae [1]
Total Authors: 10
Affiliation:
[1] Univ Sao Paulo, Fac Med FMUSP, Dept Ophthalmol, LIM 33, Sao Paulo, SP - Brazil
[2] Univ Fed Parana, Dept Ophthalmol, Curitiba, Parana - Brazil
Total Affiliations: 2
Document type: Journal article
Source: OCULAR IMMUNOLOGY AND INFLAMMATION; v. 29, n. 1 NOV 2019.
Web of Science Citations: 0
Abstract

Aims: To evaluate associations between vision-related (VR-) and health-related (HR-) QoL metrics and inflammation and treatment in non-acute VKHD patients. Methods: Cross-sectional study in a tertiary center in Sao Paulo, Brazil with 22 patients with non-acute VKHD followed prospectively for >= 12 months since acute disease onset, with systematic evaluation and predefined treatment protocols. VR- and HR-QoL aspects were assessed by VFQ-25 and SF-36 questionnaires, respectively. Associations between the questionnaire's subscale item scores with inflammation and systemic medical therapies were assessed. Results: After generalized linear model analysis, worse VA, severe fundus changes, fluctuation of VA and fluctuation of anterior chamber cells impacted negatively on VR-QoL items. Higher cumulative total dose of corticosteroids and use of immunosuppressive therapy impacted negatively on both questionnaires. Conclusion: Worse VA, clinical inflammation and systemic treatment have a significant impact on VR- and HR-QoL questionnaires. Subclinical choroidal inflammation did not seem to impact QoL. (AU)

FAPESP's process: 11/50936-7 - Vogt-Koyanagi-Harada disease: parameters for effective treatment in the acute phase and in long-standing disease
Grantee:Joyce Hisae Yamamoto Takiuti
Support type: Regular Research Grants